Microbot Medical (NASDAQ:MBOT) and Allena Pharmaceuticals (NASDAQ:ALNA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.
Insider and Institutional Ownership
5.2% of Microbot Medical shares are owned by institutional investors. Comparatively, 80.1% of Allena Pharmaceuticals shares are owned by institutional investors. 20.3% of Microbot Medical shares are owned by insiders. Comparatively, 36.7% of Allena Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
This table compares Microbot Medical and Allena Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings and Valuation
This table compares Microbot Medical and Allena Pharmaceuticals’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Microbot Medical||N/A||N/A||-$7.24 million||N/A||N/A|
|Allena Pharmaceuticals||N/A||N/A||-$35.65 million||($1.72)||-3.17|
Risk & Volatility
Microbot Medical has a beta of 5.38, suggesting that its stock price is 438% more volatile than the S&P 500. Comparatively, Allena Pharmaceuticals has a beta of 1.69, suggesting that its stock price is 69% more volatile than the S&P 500.
This is a breakdown of current recommendations and price targets for Microbot Medical and Allena Pharmaceuticals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Microbot Medical currently has a consensus price target of $1.75, suggesting a potential downside of 76.82%. Allena Pharmaceuticals has a consensus price target of $25.20, suggesting a potential upside of 362.39%. Given Allena Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Allena Pharmaceuticals is more favorable than Microbot Medical.
Allena Pharmaceuticals beats Microbot Medical on 7 of the 9 factors compared between the two stocks.
About Microbot Medical
Microbot Medical Inc., a pre-clinical medical device company, researches, designs, and develops micro-robotics assisted medical technologies targeting the minimally invasive surgery space. The company, through its ViRob and TipCAT micro-robotic technologies, is developing two product candidates, including the Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; and a self-propelling, semi-disposable endoscope, which is used in colonoscopy procedures. It also holds an intellectual property portfolio that comprises 9 patent families, which include 9 patents granted in the United States, 12 patents granted outside the United States, and 15 patent applications pending worldwide. Microbot Medical Inc. was founded in 2010 and is based in Hingham, Massachusetts.
About Allena Pharmaceuticals
Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. It also develops ALLN-346 for patients with hyperuricemia and moderate to severe chronic kidney diseases. The company was founded in 2011 and is headquartered in Newton, Massachusetts.
Receive News & Ratings for Microbot Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microbot Medical and related companies with MarketBeat.com's FREE daily email newsletter.